List view / Grid view
University of Warwick expertise is contributing to a world-first £1.5million study aiming to tackle one of the biggest public health threats we face - antibiotic resistance.
BioGeneration Ventures (BGV) announces an investment by the European Investment Fund (EIF) and other new investors in BGV III...
Cancer Research UK has launched the second phase of its global Grand Challenge by announcing eight new questions – identified as some of the biggest barriers to making progress against cancer – and inviting the world’s top scientists to come together with new proposals to tackle them.
Tech for Good company, Elemental Software, has announced that it has raised £300,000 with the help of ClearlySo, Europe’s leading impact investment bank.
The UJI has modified the regulations governing research with the aim of making it possible for assistant health lecturers to lead research groups...
Collaboration extends initial partnership and aims to generate lead antibody candidates against membrane targets using AbCellera's antibody discovery platform…
Six national Physician Assistant (PA) organisations came together this past week to identify how to impact the mental health crisis in the US.
The University of Zurich is launching a new WHO Collaborating Centre for Physical Activity and Health. The Physical Activity and Health Unit and other groups of the Epidemiology, Biostatistics and Prevention Institute will support the Physical Activity Strategy for the World Health Organization (WHO) European Region.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing 15 new Research Training Groups to further support early research...
Lyme disease – an infection contracted from the bite of an infected tick– is an important emerging disease in the UK, and is increasing in incidence in people in the UK and large parts of Europe and North America.
New diagnoses for two types of skin cancer increased in recent years, according to a Mayo Clinic-led team of researchers.
A preclinical candidate calcitonin gene-related peptide (CGRP) antagonist has been nominated for advancement into further preclinical studies as an investigational treatment for migraine.
Kymab Group Limited, a leading human monoclonal antibody biopharmaceutical group, announces the appointment of Dr Sonia Quaratino as its first Chief Medical Officer. Dr Quaratino will manage the clinical development of the Group's expanding therapeutic antibody portfolio.
Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
SMi Group’s 3rd In Vitro Diagnostics conference will be take place on the 14th & 15th of June in London, bringing together global leading experts within the medical industry as they focus on the latest international trends within the field...
